Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives

References

• Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25–29. doi:10.1016/j.ijcard.2015.05.12726404748
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Toumpourleka M, Imprialos KP, Alataki S, Manafis A, Stavropoulos K. The role of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction. Curr Pharm Des. 2018;24(46):5517–5524. doi:10.2174/138161282566619021914132630806305
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM19990902341100110471456
   PubMed Web of Science ®Google Scholar
• Manolis AA, Manolis TA, Melita H, Manolis AS. Eplerenone versus spironolactone in resistant hypertension: an efficacy and/or cost or just a men’s issue? Curr Hypertens Rep. 2019;21(3):22. doi:10.1007/s11906-019-0924-030826898
   PubMed Web of Science ®Google Scholar
• Rossello X, Ariti C, Pocock SJ, et al. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol. 2019;108(5):477–486. doi:10.1007/s00392-018-1378-030264282
   PubMed Web of Science ®Google Scholar
• Frankenstein L, Seide S, Tager T, et al. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Fail Rev. 2019. doi:10.1007/s10741-019-09832-y
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med. 2012;125(8):817–825. doi:10.1016/j.amjmed.2011.12.01822840667
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Seo Y, Ishizu T, et al. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. Heart Vessels. 2019;34(2):279–289. doi:10.1007/s00380-018-1250-130203391
   PubMed Web of Science ®Google Scholar
• Li S, Zhang X, Dong M, et al. Effects of spironolactone in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(35):e11942. doi:10.1097/MD.000000000001194230170387
   PubMed Web of Science ®Google Scholar
• Brunton L, Parker K, Blumenthal D, Buxton I. Goodman and Gilman’s Manual of Pharmacology and Therapeutics. USA: McGraw-Hill Companies, Inc; 2008.
   Google Scholar
• Binson G, Beuzit K, Migeot V, et al. Preparation and physicochemical stability of liquid oral dosage forms free of potentially harmful excipient designed for pediatric patients. Pharmaceutics. 2019;11:4. doi:10.3390/pharmaceutics11040190
   Web of Science ®Google Scholar
• Cornish P. “Avoid the crush”: hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ. 2005;172(7):871–872. doi:10.1503/cmaj.05017615795404
   PubMed Web of Science ®Google Scholar
• Blair HA. Patiromer: a review in hyperkalaemia. Clin Drug Investig. 2018;38(8):785–794. doi:10.1007/s40261-018-0675-8
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a Phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–1550. doi:10.1016/S0140-6736(19)32135-X31533906
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Butler J, Dolan CM, et al. Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia. Pharmacoeconomics. 2018;36(12):1463–1473. doi:10.1007/s40273-018-0709-330194623
   PubMed Web of Science ®Google Scholar
• Vukadinovic D, Lavall D, Vukadinovic AN, Pitt B, Wagenpfeil S, Bohm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99–108. doi:10.1016/j.ahj.2017.03.01128577687
   PubMed Web of Science ®Google Scholar
• Korol S, Mottet F, Perreault S, Baker WL, White M, de Denus S. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis. Medicine (Baltimore). 2017;96(48):e8719. doi:10.1097/MD.000000000000871929310346
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw12827206819
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392. doi:10.1056/NEJMoa131373124716680
   PubMed Web of Science ®Google Scholar
• Xiang Y, Shi W, Li Z, et al. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2019;98(13):e14967. doi:10.1097/MD.000000000001496730921200
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. doi:10.1016/j.jacc.2017.04.02528461007
   PubMed Web of Science ®Google Scholar
• Packer M. Compelling first-line drug and device therapies for the prevention of sudden death in patients with chronic heart failure and a reduced ejection fraction who are candidates for an implantable cardioverter-defibrillator. Circ Arrhythm Electrophysiol. 2019;12(6):e007430. doi:10.1161/CIRCEP.119.00743031159583
   PubMed Web of Science ®Google Scholar
• Lund LH, Svennblad B, Melhus H, Hallberg P, Dahlstrom U, Edner M. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. Circ Heart Fail. 2013;6(2):174–183. doi:10.1161/CIRCHEARTFAILURE.112.00011523386667
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Vaios V, Eleftheriadis T, Zebekakis P, Liakopoulos V. Mineralocorticoid antagonists in ESRD: an overview of clinical trial evidence. Curr Vasc Pharmacol. 2017;15(6):599–606. doi:10.2174/157016111566617020111381728155610
   PubMed Web of Science ®Google Scholar
• Jackson LD, Little J, Kung E, Williams EM, Siemiatkowska K, Plowman S. Safe medication swallowing in Dysphagia: a collaborative improvement project. Healthc Q. 2008;11(3Spec No):110–116. doi:10.12927/hcq.2008.1966018382171
   PubMedGoogle Scholar
• Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15(9):411–414.
   Google Scholar
• Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1–2):197–206. doi:10.1016/j.ijpharm.2012.04.02222525080
   PubMedGoogle Scholar
• Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377(1):41–51. doi:10.1056/NEJMoa160975828679089
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail. 2017;19(8):974–986. doi:10.1002/ejhf.2017.19.issue-828401618
   PubMed Web of Science ®Google Scholar